Genetic polymorphism of CYP1A2 increases the risk of myocardial infarction

Journal of Medical Genetics

Volumn 41, Issue 10, 2004, Pages 758-762

  Cornelis, M C ^a   El Sohemy, A ^a   Campos, H ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; MUTAGENIC AGENT; TOBACCO SMOKE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; COSTA RICA; DETOXIFICATION; DNA BINDING; DNA DAMAGE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC ACTIVATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUESTIONNAIRE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING;

COSTA RICA; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; SMOKING;

NICOTIANA TABACUM;

EID: 6344240884     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2004.022012     Document Type: Article

References (42)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
2. Ross J, Stagliano N, Danovan M, Breilbart R, Ginsburg G. Atherosclerosis: a cancer of the blood vessels? Am J Clin Pathol 2001;116(suppl 1):S97-107.
3. Penn A. Mutational events in the etiology of arteriosclerotic plaques. Mutat Res 1990;239:149-62.
4. Botto N, Rizza A, Colombo MG, Mazzone AM, Manfredi S, Masetti S, Clerica A, Biagini A, Andreassi MG. Evidence for DNA damage in patients with coronary heart disease. Mutat Res 2001;493:23-30.
5. Benditt EP, Benditt JM. Evidence for a monoclonal origin of human atherosclerotic plaques. Proc Natl Acad Sci U S A 1973;70:1753-6.
6. Murry CE, Gipaya CT, Bartosek T, Benditt EP, Schwartz SM. Monoclonality of smooth muscle cells in human atherosclerosis. Am J Pathol 1997;151:697-706.
7. Penn A, Snyder C. Arteriosclerotic plaque development is 'promoted' by polynuclear aromatic hydrocarbons. Carcinogenesis 1988;12:2185-9.
8. Albert RE, Vanderlaan M, Burns FJ, Nishizumi M. Effect of carcinogens on chicken atherosclerosis. Cancer Res 1977;37:2232-5.
9. Randerath E, Mittal D, Randerath K. Tissue distribution of covalent DNA damage in mice treated dermally with cigarette 'tar': preference for lung and heart DNA. Carcinogenesis 1988;9:75-80.
10. Izzotti A, D'Agostini F, Bagnasco M, Scatolini L, Rovida A, Balansky RM, Cesarone CF, De Flora S. Chemoprevention of carcinogen-DNA adducts and chronic degenerative diseases. Cancer Res 1994;54(suppl):1994s-8s.
11. van Schooten FJ, Hirvonen A, Maas IM, De Mol BA, Kleinjans JCS, Bell DA, Durrer JD. Putative susceptibility markers of coronary artery disease: association between VDR genotype, smoking, and aromatic DNA adduct levels in human right atrial tissue. FASEB J 1998;12:1409-17.
12. Zhang Y, Babette BW, Wang L, Schwartz J, Santella RM. Immunohistochemical detection of polycyclic aromatic hydrocarbon-DNA damage in human blood vessels of smokers and non-smokers. Atherosclerosis 1998;140:325-31.
13. Izzotti A, De Flora S, Petrilli GL, Gallagher J, Rojas M, Alexandrov K, Bartsch H, Lewtas J. Cancer biomarkers in human atherosclerotic lesions: detection of DNA adducts. Cancer Epidemiol Biomarkers Prev 1995;4:105-10.
14. Shou M, Gonzalez FJ, Gelboin H. Stereoselective epoxidation and hydration at the k-region of polycyclic aromatic hydrocarbons by cDNA-expressed cytochromes P450 1A1, 1A2, and epoxide hydrolase. Biochemistry 1996;35:15807-13.
15. Mammons GJ, Milton D, Stepps K, Guengerich FP, Tukey RH, Kadlubar F. Metabolism of carcinogenic heterocyclic and aromatic amines by recombinant human cytochrome P450 enzymes. Carcinogenesis 1997;18:851-4.
16. Turesky RJ, Constable A, Richoz J, Varga N, Markovic J, Martin MV, Guengerich FP. Activation of heterocyclic aromatic amines by rat and human liver microsomes and by purified rat and human cytochrome p450 1A2. Chem Res Toxicol 1998;11:925-36.
17. Bock KW, Schrenk D, Forster A, Griese E-U, Morike K, Brockmeier D, Eichelbaum M. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 1994;4:209-18.
18. Harper PA, Wong JMY, Lam MS, Okey AB. Polymorphisms in the human AH receptor. Chem Biol Interact 2002;141:161-87.
19. Thum T, Borlak J. Gene expression in distinct regions of the heart. Lancet 2000;355:979-83.
20. Zhao W, Parrish A, Ramos K. Constitutive and inducible expression of cytochrome P4501A1 and P4501B1 in human vascular endothelial and smooth muscle cells. In Vitro Cell Dev Biol Anim 1998;34:671-3.
21. Landi MT, Bertazzi PA, Shields PG, Clark G, Luder GW, Garte SJ, Cosma G, Caparaso NE. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics 1994;4:242-6.
22. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C to A polymorphism in intron 1 of the cytochrame P450 1A2 (CYP1A2) gene tested with caffeine. Br J Clin Pharmacol 1999;47:445-9.
23. Chida M, Yokoi T, Fukui T, Kinoshita M, Yokota J, Kamataki T. Detection of three genetic polymorphisms in the 5′flanking region and intron 1 of human CYP1A2 in Japanese population. Jpn J Cancer Res 1999;90:899-902.
24. Taningher M, Malacame D, Izzotti A, Ugolini D, Parodi S. Drug metabolism polymorphisms as modulators of cancer susceptibility. Mutat Res 1999;436:227-61.
25. Wang XL, Greco M, Sim AS, Duarte N, Wang J, Wilcken DE. Effect of CYP1A1 Mspl polymorphism on cigarette smoking related coronary artery disease and diabetes. Atherosclerosis 2002;162:391-7.
26. Hall C. Costa Rica. A geographical interpretation in historical perspective. Dellplain Latin American Studies, No. 17. Boulder, CO: Westview Press, 1985.
27. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas A-M, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation 1994;90:583-612.
28. Baylin A, Kabagambe E, Ascherio A, Spiegelman D, Campos H. Adipose tissue (alpha)-linolenic acid and nonfatal acute myocardial infarction in Costa Rica. Circulation 2003;107:1586-91.
29. Cascorbi I, Brockmoller J, Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 1996;56:4965-9.
30. Sen-Bonerjee S, Siles X, Campos H. Tobacco smoking modifies association between Gln-Arg192 polymorphism of human poraoxonase gene and risk of myocardial infarction. Arterioscler Thromb Vasc Biol 2000;20:2120-6.
31. Butler MA, Iwasaki M, Guengerich FP, Kadlubar F. Human cytochrome P450A (P-4501A2), the phenacetin O-de-elhylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci U S A 1989;86:7696-700.
32. Greenland S. A meta-analysis of coffee, myocardial infarction, and coronary death. Epidemiology 1993;4:366-74.
33. Shertzer HG, Clay CD, Center MB, Schneider SN, Nebert DW, Dalton TP. CYP1A2 protects against reactive oxygen production in mouse liver microsomes. Free Radic Biol Med 2004;36:605-17.
34. Smith AG, Davies R, Dalton TP, Miller ML, Judah D, Riley J, Gant T, Nebert DW. Intrinsic hepatic phenotype associated with the Cyp1a2 gene as shown by cDNA expression microarray analysis of the knockout mouse. EHP Toxicogenomics 2003;111:45-51.
35. Frye RF, Schneider VM, Frye CS, Feldman AM. Plasma levels of TNF-[alpha] and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J Card Fail 2002;8:315-9.
36. Sachse C, Bhambra U, Smith G, Lightfoot TJ, Barrett JH, Scollay J, Garner RC, Boobis AR, Wolf CR, Gooderham MI. The Colorectal Cancer Study Group. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol 2003;55:68-76.
37. Persson I, Johansson I, Ingelman-Sundberg M. In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem Biophys Res Commun 1997;231:227-30.
38. MacLeod S, Rashmi S, Kadlubor F, Nicholas P. Polymorphisms of CYP1A1 and GSTM1 influence the in vivo function of CYP1A2. Mutat Res 1997;376:135-42.
39. Li R, Boerwinkle E, Olshan AF, Chambless LE, Pankow JS, Tyroler HA, Bray M, Pittman GS, Bell DA, Heiss G. Glutathione S-transferase genotype as a susceptibility factor in smoking-related coronary heart disease. Atherosclerosis 2000;149:451-62.
40. Wang X, Greco M, Sim A, Duarte N, Wang J, Wilcken D. Glutalhione S-transferase mu1 deficiency, cigarette smoking and coronary artery disease. J Cardiovasc Risk 2002;9:25-31.
41. Wilson MH, Grant PJ, Kain K, Warner DP, Wild CP. Association between the risk of coronary artery disease in South Asians and a deletion polymorphism in glutalhione S-transferase M1. Biomarkers 2003;8:43-50.
42. Olshan AF, Li R, Pankow JS, Bray M, Tyroler HA, Chambless LE, Boerwinkle E, Pittman GS, Bell DA. Risk of atherosclerosis: interaction of smoking and glutathione S-transferase genes. Epidemiology 2003;14:321-7.